Skip to Main Content

Author Details

Davey M Smith
University of California San Diego
2001
339
64
PMIDPaper TitleJournal TitlePublished Year
36454551Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.JAMA2023
37751407Identification of system-level features in HIV migration within a host.PLoS One2023
35732421Lessons learned from the Last Gift study: ethical and practical challenges faced while conducting HIV cure-related research at the end of life.J Med Ethics2023
35723411Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.Clin Infect Dis2023
37317962Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy.J Clin Invest2023
37252012A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life.Pathog Immun2023
37384622Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies.PLoS Pathog2023
37440872Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United States.J Virus Erad2023
36697311Predictors of COVID-19 vaccine uptake among people who inject drugs.Vaccine2023
36865544CD4<sup>+</sup> T cells expressing CX3CR1, GPR56, with variable CD57 are associated with cardiometabolic diseases in persons with HIV.Front Immunol2023
36601684Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials.Clin Transl Sci2023
32571176Do Sexual Minorities Face Greater Risk for Sexual Harassment, Ever and at School, in Adolescence? : Findings From a 2019 Cross-Sectional Study of U.S. Adults.J Interpers Violence2022
35709166Characterizing genetic transmission networks among newly diagnosed HIV-1 infected individuals in eastern China: 2012-2016.PLoS One2022
35767270Internet Searches for Abortion Medications Following the Leaked Supreme Court of the United States Draft Ruling.JAMA Intern Med2022
35611335Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.Res Sq2022
35797235Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.Clin Pharmacol Ther2022
35793677Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.Cell Rep Med2022
35632788SARS-CoV-2 Seroconversion in an Adult Horse with Direct Contact to a COVID-19 Individual.Viruses2022
35364600Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March-December 2020.J Acquir Immune Defic Syndr2022
35778845Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study.AIDS Res Hum Retroviruses2022
35995785Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.Nat Commun2022
35891473Comparative Dynamics of Delta and Omicron SARS-CoV-2 Variants across and between California and Mexico.Viruses2022
35982660Viral and Symptom Rebound in Untreated COVID-19 Infection.medRxiv2022
36260191Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program.Curr HIV/AIDS Rep2022
35947674Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques.Sci Transl Med2022
35012544Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States.BMC Med Ethics2022
35172129Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status.Cell Host Microbe2022
35112782Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: A cohort study.Diabetes Obes Metab2022
35234862Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs.Clin Infect Dis2022
35323030Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.AIDS Res Hum Retroviruses2022
34750292Sex differences in type 2 diabetes mellitus prevalence among persons with HIV.AIDS2022
34570513Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.J Med Chem2022
34117753Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.Clin Infect Dis2022
33394616HIV Care Prioritization Using Phylogenetic Branch Length.J Acquir Immune Defic Syndr2021
33521695Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.Cell Rep Med2021
33798764Methodological approaches for the prediction of opioid use-related epidemics in the United States: a narrative review and cross-disciplinary call to action.Transl Res2021
33688655Negligible impact of SARS-CoV-2 variants on CD4 [+] and CD8 [+] T cell reactivity in COVID-19 exposed donors and vaccinees.bioRxiv2021
33632140Monitoring HIV testing and pre-exposure prophylaxis information seeking by combining digital and traditional data.BMC Infect Dis2021
33631357RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.Contemp Clin Trials2021
33631122Revealing Tissue-Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived Lung and Cerebral Organoids.Stem Cell Reports2021
35018382Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.medRxiv2021
34492694Effective Human Immunodeficiency Virus Molecular Surveillance Requires Identification of Incident Cases of Infection.Clin Infect Dis2021
34663375Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States.AIDS Res Ther2021
34545376Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy.medRxiv2021
34838159Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.Cell2021
34327248Can't Work From Home: Pooled Nucleic Acid Testing of Laboratory Workers During the COVID-19 Pandemic.Open Forum Infect Dis2021
33961823METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection.Cell Rep2021
33936671Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.Clin Case Rep2021
34270612Ethical and practical considerations for interventional HIV cure-related research at the end-of-life: A qualitative study with key stakeholders in the United States.PLoS One2021
33961653Attitudes and perceptions of next-of-kin/loved ones toward end-of-life HIV cure-related research: A qualitative focus group study in Southern California.PLoS One2021
  • 1 - 50 of 339

Recommended Authors

Yale School of Medicine, Yale University
Career Start Year 2014
Number of shared co-authors 3
University of Nebraska Medical Center
Career Start Year 2011
Number of shared co-authors 0
University of North Carolina at Chapel Hill
Career Start Year 2010
Number of shared co-authors 5
Johns Hopkins Bloomberg School of Public Health
Career Start Year 2009
Number of shared co-authors 4
Department of Epidemiology and Johns Hopkins Bloomberg School of Public Health
Career Start Year 2009
Number of shared co-authors 7
School of Public Health, Brown University
Career Start Year 2007
Number of shared co-authors 1
Institute of Medical Virology, University of Zurich
Career Start Year 2006
Number of shared co-authors 5
University of California San Francisco
Career Start Year 2002
Number of shared co-authors 8
University of California san francisco
Career Start Year 2002
Number of shared co-authors 15
National Institute of Allergy and Infectious Diseases
Career Start Year 2001
Number of shared co-authors 2
Kaiser Permanente Northern California
Career Start Year 2001
Number of shared co-authors 8
Northwestern University Feinberg School of Medicine
Career Start Year 2000
Number of shared co-authors 4
Lausanne University Hospital, University of Lausanne
Career Start Year 1999
Number of shared co-authors 4
Department of Medicine Johns Hopkins Medicine. Baltimore MD 21205USA.
Career Start Year 1996
Number of shared co-authors 9
Harvard TH Chan School of Public Health
Career Start Year 1996
Number of shared co-authors 8
Kaiser Permanente San Francisco Medical Center
Career Start Year 1994
Number of shared co-authors 5
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity
Career Start Year 1993
Number of shared co-authors 17
Inc., Frederick National Laboratory for Cancer Research
Career Start Year 1993
Number of shared co-authors 5
Hospital Germans Trias i Pujol
Career Start Year 1992
Number of shared co-authors 10
Johns Hopkins School of Medicine, Johns Hopkins University
Career Start Year 1990
Number of shared co-authors 9
Harvard School of Public Health
Career Start Year 1989
Number of shared co-authors 10
Instituto de Investigacion Hospital 12 de Octubre (imas12)
Career Start Year 1988
Number of shared co-authors 4
Sacramento Medical Center, Kaiser Permanente Northern California
Career Start Year 1988
Number of shared co-authors 3
La Paz University Hospital
Career Start Year 1988
Number of shared co-authors 7
University of Nebraska Medical Center
Career Start Year 1987
Number of shared co-authors 10
VA Medical Center
Career Start Year 1986
Number of shared co-authors 1
Case Western Reserve University
Career Start Year 1981
Number of shared co-authors 3
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Career Start Year 1979
Number of shared co-authors 9
Vir Biotechnology Inc.
Career Start Year 1977
Number of shared co-authors 13
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 1972
Number of shared co-authors 15

Collaborators

Co-authored papers 109
Center for AIDS Research, University of California San Diego
Co-authored papers 89
Co-authored papers 50
University of California, university of california san diego
Co-authored papers 37
University of California
Co-authored papers 29
University of California San Diego
Co-authored papers 21
University of California
Co-authored papers 19
Co-authored papers 19
University of California
Co-authored papers 14
University of Houston
Co-authored papers 13
Co-authored papers 13
Co-authored papers 13
School of Public Health, university of california san diego
Co-authored papers 12
University of Washington
Co-authored papers 11
Illumina Inc.
Co-authored papers 11
Co-authored papers 10
University of California San Diego
Co-authored papers 10
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology
Co-authored papers 10
Vitalant Research Institute, USA University of California san francisco
Co-authored papers 9
Co-authored papers 9
University of Washington School of Medicine
Co-authored papers 8
AntiViral Research Center, University of California, San Diego School of Medicine.
Co-authored papers 8
University of Washington
Co-authored papers 8
Washington University School of Medicine
Co-authored papers 7
University of California San Diego
Co-authored papers 7
Co-authored papers 7
Herbert Wertheim School of Public Health, university of california san diego
Co-authored papers 7
The University of North Carolina School of Medicine
Co-authored papers 7
University of California San Diego
Co-authored papers 6
Icahn School of Medicine at Mount Sinai
Co-authored papers 6